A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women

References

• Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M. 2004. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. European Journal of Contraception and Reproductive Health Care 9:267–277.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Primiero FM, Farris M. 2004. Clinical profile of contraceptive progestins. European Journal of Contraception and Reproductive Health Care 9:182–193.
   PubMed Web of Science ®Google Scholar
• Böttcher B, Wildt L. 2014. New and emerging contraceptive options: a focus on transdermal contraception. Open Access Journal of Contraception 5:1–5.
   Google Scholar
• Burkman RT. 2007. Transdermal hormonal contraception: benefits and risks. American Journal of Obstetrics and Gynecology 197:134.e1–6.
   PubMed Web of Science ®Google Scholar
• Burkman R, Schlesselman J, Zieman M. 2004. Safety concerns and health benefits associated with oral contraception. American Journal of Obstetrics and Gynecology 190:S5e22.
   Web of Science ®Google Scholar
• Corbelli J, Shaikh N, Wessel C, Hess R. 2015. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause 22:114–121.
   PubMed Web of Science ®Google Scholar
• Daniels K, Daugherty J, Jones J. 2014. Current contraceptive status among women aged 15–44: United States, 2011–2013. National Center for Health Statistics Data Brief 173:1–8.
   Google Scholar
• Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD et al. 2007. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. The Journal of Clinical Pharmacology 47:497–509.
   PubMed Web of Science ®Google Scholar
• Goldzieher JW, Stanczyk FZ. 2008. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception 78:4–9.
   PubMed Web of Science ®Google Scholar
• Gruber, D, Skřivánek A, Serrani M, Lanius V, Zurth C, Merz, M. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study. Poster presented at the annual meeting of the European Society for Human Reproduction and Embryology, London, United Kingdom; 7–10 July 2013.
   Google Scholar
• Heger-Mahn D, Warlimont C, Faustmann T, Gerlinger C, Klipping C. 2004. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. European Journal of Contraception and Reproductive Health Care 9:173–181.
   PubMed Web of Science ®Google Scholar
• Hofmann B, Reinecke I, Schuett B, Merz M, Zurth C. 2014. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive. International Journal of Clinical Pharmacology and Therapeutics 52:1059–1070.
   PubMed Web of Science ®Google Scholar
• Hoogland HJ, Skouby SO. 1993. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 47:583–590.
   PubMed Web of Science ®Google Scholar
• Jung-Hoffmann C, Kuhl H. 1990. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception 42:423–438.
   PubMed Web of Science ®Google Scholar
• Junge W, Heger-Mahn D, Trummer D, Merz M. 2013. Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study. Drugs in R & D 13:223–233.
   Google Scholar
• Kuhl H. 2005. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8 (Suppl 1): 3–63.
   PubMed Web of Science ®Google Scholar
• Kuhnz W, Blode H, Zimmerman H. 1999. Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens. In: Oettel M, Schillinger E, editors, Estrogens and Antiestrogens II. Berlin. Springer Berlin Heidelberg; pp 261–322.
   Google Scholar
• Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A et al. 2013. Hormonal contraceptives for contraception in overweight or obese women. The Cochrane Database of Systematic Reviews 4:CD008452.
   Google Scholar
• Merz M, Grunert J. 2014. Effects of an ethinyl estradiol/gestodene transdermal contraceptive patch on the endometrium: a single-center, uncontrolled study. Womens Health 10:37–43.
   Google Scholar
• Nelson HD. 2004. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. Journal of the American Medical Association 291:1610–1620.
   PubMed Web of Science ®Google Scholar
• Soares CN, Almeida OP, Joffe H, Cohen LS. 2001. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry 58:529–534.
   PubMed Web of Science ®Google Scholar
• Stephenson K, Kurdowska A, Neuenschwander P, Olusola P, Brown S, Kapur S et al. 2013. Physiologic transdermal sex steroid hormone replacement therapy and effects on cardiovascular biomarkers, quality of life, and age-related decline in peri/postmenopausal women. Circulation 127:AP039.
   PubMed Web of Science ®Google Scholar
• United Nations Department of Economic and Social Affairs. World Contraceptive Use. 2011. Available at: http://www.un.org/esa/population/publications/contraceptive2011/contraceptive2011.htm. [Last accessed: 12 Feb 2015]
   Google Scholar
• van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. 2005. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72:168–174.
   PubMed Web of Science ®Google Scholar
• Westhoff C, Reinecke I, Bangerter K, Merz M. 2014. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55 mg ethinyl estradiol/2.1 mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles. Contraception 90:272–279.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Bassol S, Weisberg E, Mellinger U, Merz M. 2014. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study. Reproductive Sciences 21:1518–1525.
   PubMed Web of Science ®Google Scholar
• Wilde MI, Balfour JA. 1995. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 50:364–395.
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. 2002. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertility and Sterility 77: S13–18.
   PubMed Web of Science ®Google Scholar